Paper Details

  1. Home
  2. Paper Details

A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.

Author: BreemsDimitri, ChanGeoffrey, ChingKeith, Gallo StampinoCorrado, GyanEmmanuel, JorisMagalie, KovacsovicsTibor, KrauterJürgen, KudlaArthur, MaWeidong Wendy, MaertensJohan, O'BrienThomas, SchusterMichael, SekeresMikkael A, VermaAmit, VyasParesh, WangEunice S, ZeidanAmer M

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This phase 1b study evaluated glasdegib (100 mg once daily) + azacitidine in adults with newly diagnosed acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) who were ineligible for intensive chemotherapy. The safety profile of glasdegib + azacitidine was determined to be consistent with those of glasdegib or azacitidine alone. In the expansion cohort, the most frequently reported non-hematologic Grade ≥ 3 treatment-emergent adverse events were decreased appetite, electrocardiogram QT prolongation, and hypertension in the AML cohort and sepsis, diarrhea, hypotension, pneumonia, and hyperglycemia in the MDS cohort. Overall response rates in the AML and MDS cohorts were 30.0% and 33.3%, respectively. Median overall survival was 9.2 months and 15.8 months, respectively, and response was associated with molecular mutation clearance. Glasdegib + azacitidine in patients with newly diagnosed AML or MDS demonstrated an acceptable safety profile and preliminary evidence of clinical benefits.
Paper Details　
Original Abstract of the Article :
This phase 1b study evaluated glasdegib (100 mg once daily) + azacitidine in adults with newly diagnosed acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) who were ineligible for intensive chemotherapy. Of 72 patients enrolled, 12 we...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00277-022-04853-4

データ提供：米国国立医学図書館（NLM）

Glasdegib + Azacitidine: A New Combination Therapy for AML and MDS

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are serious blood cancers that require aggressive treatment. This study explores a novel combination therapy using glasdegib and azacitidine for patients with newly diagnosed AML, higher-risk MDS, or chronic myelomonocytic leukemia (CMML) who are ineligible for intensive chemotherapy. The researchers evaluated the safety and efficacy of this combination therapy, seeking to offer a viable treatment option for patients who cannot tolerate traditional therapies.

A New Oasis in the Desert of Blood Cancers

The study found that the combination of glasdegib and azacitidine was well-tolerated, with a safety profile similar to that of each drug alone. Moreover, the combination therapy showed promising signs of clinical benefit, with significant response rates in both the AML and MDS cohorts. It's like discovering a new oasis in the vast desert of blood cancer treatment, offering a potentially effective and well-tolerated approach.

Improving Outcomes for Blood Cancer Patients: A Multifaceted Approach

This research underscores the importance of developing novel treatment strategies for blood cancers. It's like exploring new paths through a challenging desert, seeking a more effective and less arduous route. This combination therapy offers a promising approach for patients who are ineligible for intensive chemotherapy, offering the potential to improve their outcomes and quality of life.

Dr.Camel's Conclusion

This research on glasdegib and azacitidine is like finding a new source of water in the desert of blood cancer treatment. This combination therapy offers a potentially effective and well-tolerated approach for patients who cannot tolerate traditional therapies. It's a reminder that even in the most challenging landscapes of disease, there is always hope for new discoveries and better treatments.

Date :
  1. Date Completed 2022-07-15
  2. Date Revised 2023-03-15
Further Info :

Pubmed ID

35488900

DOI: Digital Object Identifier

10.1007/s00277-022-04853-4

Related Literature

Article Analysis
・Effects of glasdegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.